- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Systemic lupus erythematosus
- Meeting Date: March 2023
- Public Summary Document (PSD) March 2023 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) March 2023 PBAC Meeting - (Word 529KB)
Anifrolumab – March 2023
Anifrolumab: Solution concentrate for I.V. infusion 300 mg in 2 mL vial; Saphnelo®
Last updated
30 June 2023